- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01132235
An Open-label Study to Evaluate the Efficacy of Re-treatment for Patients With a History of Etanercept Use (ENBRECAP2009)
Studieoversikt
Studietype
Registrering (Forventet)
Fase
- Fase 4
Kontakter og plasseringer
Studiesteder
-
-
Florida
-
Miami, Florida, Forente stater, 33136
- Rekruttering
- Florida Academic Dermatology Center
-
Ta kontakt med:
- Annika M Grant, RN.MBA
- Telefonnummer: 210 305-324-2110
- E-post: annikagrant@bellsouth.net
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Subjects with psoriasis who have previously been treated with etanercept for a minimum of 6 months and discontinued treatment due to loss of efficacy. Every attempt will be made to obtain loss of efficacy history from the subject's medical chart;when etanercept was commenced and terminated and description of patient's psoriasis on termination and details of new treatment commenced. Subjects must have failed their latest psoriasis treatment after a period of three months. This will be measured as a PGA of ≥ 3.
- There is no specific requirement as to when prior treatment with etanercept occurred and no requirement as to what type of treatment(s) used between initial and subsequent treatments.
- Are ≥ 18 years of age
- PGA ≥ 3
- BSA minimum of 5%
Tuberculosis inclusion criteria
- Have no history of latent or active TB prior to screening.
- Have no signs or symptoms suggestive of active TB upon medical history and/or physical examination.
- Have had no recent close contact with a person with active TB.
Within 1 month prior to the first administration of study have a negative tuberculin skin test.
- The ability to give written informed consent and comply with study procedures.
Exclusion Criteria:
- Current enrollment in any other investigational device or investigational drug trial(s), or receipt of any other investigational agent(s) within 28 days before baseline visit.
- Known hypersensitivity to Enbrel® (etanercept) or any of its components or known to have antibodies to etanercept.
- Latex sensitivity [NB: only applicable if they are using prefilled syringe or prefilled SureClick™ autoinjector presentations]
- Prior or concurrent use of cyclophosphamide therapy
- Concurrent sulfasalazine therapy.
- A positive HBV test or known history of any other immuno-suppressing disease.
- Any mycobacterial disease or high risk factors for tuberculosis (TB), such as family member with TB, positive purified protein derivative (PPD) or taking anti-tuberculosis medication.
- Active or chronic infection within 4 weeks before screening visit, or between the screening and baseline visits.
- History of listeriosis, histoplasmosis, chronic or active Hepatitis B infection and Hepatitis C, human immunodeficiency virus (HIV) infection, immunodeficiency syndrome, chronic recurring infections or active TB, or other opportunistic infections
- If etanercept was previously discontinued due to a serious adverse event
- Severe comorbidities (diabetes mellitus requiring insulin; CHF of any severity; or myocardial infarction, cerebrovascular accident or transient ischemic attack within 6 months of screening visit; unstable angina pectoris; uncontrolled hypertension (sitting systolic BP <80 mm Hg or > 160 or diastolic BP > 100 mm Hg); oxygen-dependent severe pulmonary disease; history of cancer within 5 years [other than resected cutaneous basal or squamous cell carcinoma of the skin or in situ cervical cancer])
- Systemic lupus erythematosus, history of multiple sclerosis, transverse myelitis, optic neuritis or seizure disorder.
- Use of a live vaccine 90 days prior to screening visit, or concurrent use of a live vaccine.
- Any condition or circumstances judged by the patient's physician [or the investigator or medically qualified study staff] to render this clinical trial detrimental or otherwise unsuitable for the patient's participation.
- Female subjects who are pregnant, nursing or planning pregnancy (both men and women) and not using acceptable methods of birth control during the trial (hormonal, barriers, abstinence).
- Women who are breast feeding
History of non-compliance with other therapies.
- History of alcohol abuse within the last 12 months
- Concurrent use of anakinra
- Subjects who cannot discontinue any of the drugs below for 2 weeks prior to the baseline visit or during the study;
A two week wash out period is appropriate as it would be unethical to expect subjects whose disease if flaring to remain untreated for a longer period of time. The first dose of etanercept will be administered two weeks after the last biologic dose.
- Immunosuppressants, antimalarials, or sulfasalazine.
- Other Ani-TNFs
- Cyclosporine
- Efalizumab
- Azathioprine
- Hydroxyurea
- Live vaccines
- Tacrolimus
- Oral retinoids (isotretinoin,acitretin,bexarotene)
- Ultra violet light therapies
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
The proportion of patients achieving a Physician's Global Assessment (PGA) score of minimal (1) or clear (0) at week 12.
Tidsramme: 12 weeks
|
Physician's Global Assessment (PGA) score of minimal (1) or clear (0) at week 12 will measure efficacy of retreatment with etanercept
|
12 weeks
|
Samarbeidspartnere og etterforskere
Samarbeidspartnere
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Forventet)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Hudsykdommer
- Hudsykdommer, Papulosquamous
- Psoriasis
- Fysiologiske effekter av legemidler
- Agenter fra det perifere nervesystemet
- Analgetika
- Sensoriske systemagenter
- Anti-inflammatoriske midler, ikke-steroide
- Analgetika, ikke-narkotisk
- Anti-inflammatoriske midler
- Antirevmatiske midler
- Immunsuppressive midler
- Immunologiske faktorer
- Gastrointestinale midler
- Etanercept
Andre studie-ID-numre
- ENBRECAP2009
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Psoriasis
-
ProgenaBiomeRekrutteringPsoriasis | Psoriasis Vulgaris | Psoriasis i hodebunnen | Psoriatisk plakk | Psoriasis Universalis | Psoriasis ansikt | Psoriasis negl | Psoriasis Diffusa | Psoriasis Punctata | Psoriasis Palmaris | Psoriasis Circinata | Psoriasis Annularis | Psoriasis Genital | Psoriasis GeographicaForente stater
-
Clin4allRekrutteringPsoriasis i hodebunnen | Psoriasis negl | Psoriasis Palmaris | Psoriasis Genital | Psoriasis PlantarisFrankrike
-
Centre of Evidence of the French Society of DermatologyRekrutteringPsoriasis | Psoriasis Vulgaris | Psoriasis i hodebunnen | Psoriatisk plakk | Psoriasis Universalis | Psoriasis Palmaris | Psoriatisk erytrodermi | Psoriasis negl | Psoriasis Guttate | Psoriasis invers | Psoriasis pustulærFrankrike
-
AmgenFullførtPsoriasis-type psoriasis | Plakk-type psoriasisForente stater
-
Innovaderm Research Inc.FullførtPsoriasis i hodebunnen | Pustuløs Palmo-plantar Psoriasis | Ikke-pustulær Palmo-plantar Psoriasis | Psoriasis i albuen | Psoriasis i underbenetCanada
-
UCB Biopharma S.P.R.L.FullførtModerat til alvorlig psoriasis | Generalisert pustuløs psoriasis og erytrodermisk psoriasisJapan
-
TakedaRekrutteringGeneralisert pustulær psoriasis | Erytrodermisk psoriasisJapan
-
Janssen Pharmaceutical K.K.RekrutteringGeneralisert pustulær psoriasis | Erytrodermisk psoriasisJapan
-
Eli Lilly and CompanyFullførtGeneralisert pustulær psoriasis | Erytrodermisk psoriasisJapan
-
PfizerFullførtPsoriasis Vulgaris | Pustuløs psoriasis | Psoriasis Arthropathica | Erytrodermisk psoriasisJapan
Kliniske studier på etanercept
-
EMSTilbaketrukket
-
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...FullførtAnkyloserende spondylittKina
-
Shanghai Celgen Bio-Pharmaceutical Co.,LtdUkjentPsoriasis | Plakk PsoriasisKina
-
AmgenFullførtLeddgikt, revmatoid; Leddgikt, psoriasisForente stater, Puerto Rico
-
mAbxience Research S.L.Rekruttering
-
Sun Yat-sen UniversityFullført
-
Samsung Bioepis Co., Ltd.Fullført
-
AmgenFullført
-
AmgenFullført
-
Sun Pharmaceutical Industries LimitedTilbaketrukket